Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D 0001892421 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 02/26/2025 false 0001130166 23254L801 Cyclacel Pharmaceuticals, Inc. 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 Datuk Dr. Doris Wong Sing Ee 60 (12) 223 7897 Level 10, Tower 11, Ave. 5, No. 8, Jalan Kerinchi, Bangsar South Wilayah Persekut Kuala Lumpur N8 59200 0001892421 N Doris Wong Sing Ee OO N N8 194628820.00 0.00 194628820.00 0.00 194628820.00 N 70.0 IN Based on 246,357,569 shares outstanding on February 28, 2025 Common Stock, par value $0.0001 per share Cyclacel Pharmaceuticals, Inc. 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 Datuk Dr. Doris Wong Sing Ee is a citizen of Malaysia. Datuk Dr. Doris Wong Sing Ee's present principal occupation is Chief Executive Officer and Executive Director of the Issuer. Datuk Dr. Doris Wong Sing Ee's business address is 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922. The Reporting Person is a private investor. During the last five years, Datuk Dr. Doris Wong Sing Ee (i) has not been convicted in any criminal proceeding (excluding traffic violations), and (ii) has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Person has not, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Person is a citizen of Malaysia. The shares of common stock were purchased by Datuk Dr. Doris Wong Sing Ee in a private transaction pursuant to a certain Securities Purchase Agreement, between the Reporting Person and a certain shareholder of the Issuer, for the aggregate purchase price of $6.3M. The purchase transaction closed on February 26, 2025. Datuk Dr. Doris Wong Sing Ee purchased the shares pursuant to the Securities Purchase Agreement. In connection with the purchase, Datuk Dr. Doris Wong Sing Ee was appointed as Chief Executive Office and as an Executive Director of the Issuer. Subject to ongoing evaluation, except as set forth above, the Reporting Person has no current plans or proposals which relate to or would result in any of the following: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization, or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure, including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940; (g) Changes in the Issuer's charter, bylaws, or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) Any action similar to any of those enumerated above. See also Item 3. The Reporting Person has the sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the 194,628,820 shares of common stock (the "Shares") of the Issuer. The percentage of Shares reported to be beneficially owned by the Reporting Person is based on information from the Issuer. Thus, the Reporting Person is deemed to be the beneficial owner of an aggregate 70.0% of the common stock of the Issuer. The Reporting Person has the sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the 194,628,820 shares of common stock (the "Shares") of the Issuer. The percentage of Shares reported to be beneficially owned by the Reporting Person is based on information from the Issuer. Thus, the Reporting Person is deemed to be the beneficial owner of an aggregate 70.0% of the common stock of the Issuer. Except as described in Item 4, during the past 60 days, the Reporting Person has not effected any transactions with respect to the shares of common stock of the Issuer. Not applicable. Not applicable. Reference is made to the transaction stated in Item 3 above. Exhibit A - Securities Purchase Agreement (incorporated by reference from the Current Report on Form 8-K filed by the Issuer on February 27, 2025. https://www.sec.gov/Archives/edgar/data/1130166/000182912625001253/cyclacel_ex10-1.htm Doris Wong Sing Ee /s/ Datuk Dr. Doris Wong Sing Ee Chief Executive Officer 03/04/2025